Daichirona (monovalent, Omicron XBB.1.5)

Partial Change Approval

Coronavirus (SARS-CoV-2) RNA Vaccine (active ingredient: MAFB-7256a)

Approval Information

Brand NameDaichirona (monovalent, Omicron XBB.1.5)

Generic NameCoronavirus (SARS-CoV-2) RNA Vaccine (active ingredient: MAFB-7256a)

ApprovedNovember 2023

TypePartial Change Approval

Review Reports

English Review Report

PDF · 595.71 KB

Japanese Review Report

PDF · 494.45 KB

Want structured data, translation summaries & alerts?

PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.

Join the Waitlist

Source: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.

← Back to Drug Database